RMD vs EW vs ABT Stock Comparison

Resmed, Edwards Lifesciences and Abbott Laboratories Prices as of Nov 13, 2026 Peers: Industry group
RMD Resmed Inc
$239.53 +1.7% 1M -5.0% 1Y
Market cap
$34.16B
P/E
21.4x
Revenue (TTM)
$5.73B
Div. yield
–
Medical Devices Healthcare
6 wins
EW Edwards Lifesciences Corp
$107.18 +24.0% 1M +24.5% 1Y
Market cap
$61.58B
P/E
60.7x
Revenue (TTM)
$6.67B
Div. yield
–
Medical Devices Healthcare
4 wins
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$186.63B
P/E
39.7x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
1 win

Head to Head

11 decided of 12

Resmed leads on 6 of the 12 questions below (Resmed 6, Edwards Lifesciences 4, Abbott Laboratories 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRMDEWABTLeader
Larger companyMarket capitalisation $34.16B $61.58B $186.63B ABT
Cheaper on earningsLower P/E, profitable companies only 21.4x 60.7x 39.7x RMD
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.5x 37.6x 19.1x RMD
Faster revenue growthRevenue growth, trailing twelve months +9.0% +13.4% +10.0% EW
More profitableNet margin, trailing twelve months 27.8% 15.2% 9.7% RMD
Better return on capitalReturn on invested capital 22.0% 8.7% 5.7% RMD
Less leveragedLower net debt / EBITDA -0.3x -2.5x 2.5x EW
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.02% –
Better 1-year returnPrice return, last 12 months -5.0% +24.5% -16.0% EW
Better 5-year returnAnnualised price return, 5 years -1.2%/yr -1.6%/yr -3.3%/yr RMD
Less volatileAnnualised volatility, 1 year 31.1% 25.5% 28.5% EW
Higher overall scoreMean of the five percentile scores vs peers 80/100 77/100 56/100 RMD

Percentile Scorecard

RMDEWABT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRMDEWABT
Valuation 75 #62 of 243 61 #96 of 243 74 #65 of 243
Growth 60 #92 of 228 57 #99 of 228 26 #168 of 228
Profitability 99 #3 of 222 96 #10 of 222 82 #41 of 222
Financial Health 76 #61 of 248 87 #34 of 248 33 #167 of 248
Shareholder Returns 89 #18 of 158 84 #26 of 158 65 #56 of 158
Overall 80 77 56
  • RMD ranked among 252 companies in Medical Devices and Diagnostics
  • EW ranked among 252 companies in Medical Devices and Diagnostics
  • ABT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRMDEWABTSPY
1 month +1.7%+24.0%+5.4% -2.0%
3 months +6.7%+17.0%-2.4% -2.8%
6 months +18.6%+31.7%+28.5% +2.0%
Year to date -0.6%+25.7%-13.4% +10.6%
1 year -5.0%+24.5%-16.0% +12.2%
3 years +62.6%+62.9%+11.8% +68.1%
3 years, per year +17.6%+17.7%+3.8% +18.9%
5 years -6.0%-7.6%-15.5% +61.4%
5 years, per year -1.2%-1.6%-3.3% +10.1%
10 years +300.2%+253.3%+170.4% +248.5%
10 years, per year +14.9%+13.5%+10.5% +13.3%

Risk

MeasureRMDEWABTSPY
Volatility, 1Y 31.1%25.5%28.5% 13.6%
Downside volatility, 1Y 33.9%24.7%27.8% 13.9%
Beta vs S&P 500, 1Y 0.510.580.07 1.00
Return / volatility, 1Y -0.160.96-0.56 0.90
Max drawdown, 5Y -49.8%-54.3%-41.6% -25.4%
From 52-week high -13.2%0.0%-16.9% -3.2%
52-week high $275.96$107.18$130.59 $779.14
52-week low $182.82$75.87$82.56 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRMDEWABT
P/E now vs peer median 21.5xmedian 26.5x 60.9xmedian 26.5x 40.0xmedian 26.5x
P/S now vs peer median 5.9xmedian 2.7x 9.2xmedian 2.7x 3.9xmedian 2.7x
EV/EBITDA now vs peer median 15.8xmedian 18.4x 35.8xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 20.9xmedian 25.4x 43.3xmedian 25.4x 27.8xmedian 25.4x
P/B now vs peer median 5.7xmedian 2.5x 5.6xmedian 2.5x 3.6xmedian 2.5x
PEG now vs peer median 0.99median 0.98 -6.65median 0.98 -13.92median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRMDEWABT
Revenue $5.73B $6.67B $48.23B
Gross profit $3.50B $5.21B $27.46B
Operating income $1.89B $1.44B $6.65B
Net income $1.59B $1.02B $4.70B
Free cash flow $1.61B $1.42B $6.76B
R&D $393.82M $1.09B $3.31B
EPS (diluted) $11.11 $1.76 $2.70
Cash & equivalents $1.01B $3.11B $4.05B
Total debt $409.60M $598.80M $31.16B
Shares (diluted) 143.41M 577.60M 1.74B
Enterprise value $28.60B $44.79B $160.49B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRMDEWABT
P/E 21.5x 60.9x 40.0x
P/FCF 20.9x 43.3x 27.8x
P/Operating cash flow 19.0x 35.9x 21.2x
P/S 5.9x 9.2x 3.9x
P/B 5.7x 5.6x 3.6x
P/Tangible book 6.1x 6.3x 5.9x
EV/EBITDA 15.8x 35.8x 20.3x
EV/EBIT 17.5x 40.0x 32.3x
EV/Revenue 5.8x 8.6x 4.5x
EV/FCF 20.6x 40.5x 31.8x
EV/Operating cash flow 18.7x 33.6x 24.3x
PEG (3Y EPS CAGR) 0.99 -6.65 -13.92

Growth

14 metrics
MetricRMDEWABT
Revenue growth (1Y) 9.0% 13.4% 10.0%
Revenue CAGR (3Y) 9.4% 16.9% 6.5%
Gross profit growth (1Y) 11.0% 13.2% 12.1%
Gross profit CAGR (3Y) 13.2% 13.7% 7.8%
Operating income growth (1Y) 8.5% 1.1% -13.8%
Operating income CAGR (3Y) 18.2% 5.8% 3.5%
Net income growth (1Y) 10.8% -25.2% -66.4%
Net income CAGR (3Y) 20.7% -10.6% -3.1%
EPS growth (1Y) 13.5% -24.5% -66.1%
EPS CAGR (3Y) 21.8% -9.2% -2.9%
Operating cash flow growth (1Y) -6.0% 68.9% -2.9%
Operating cash flow CAGR (3Y) 23.7% 18.1% 10.6%
Free cash flow growth (1Y) -9.0% 77.1% -2.3%
Free cash flow CAGR (3Y) 25.5% 20.8% 14.6%

Profitability

14 metrics
MetricRMDEWABT
Gross margin 61.1% 78.0% 56.9%
EBITDA margin 36.4% 24.2% 21.9%
Operating margin 33.0% 21.6% 13.8%
Pretax margin 35.1% 21.5% 13.6%
Net margin 27.8% 15.2% 9.7%
FCF margin 28.1% 21.3% 14.0%
Operating cash flow margin 30.9% 25.7% 18.4%
Return on equity 25.4% 9.4% 9.1%
Return on assets 18.5% 7.2% 4.3%
Return on invested capital 22.0% 8.7% 5.7%
Return on capital employed 26.1% 11.6% 7.2%
Asset turnover 0.7x 0.5x 0.4x
Cash conversion (OCF / net income) 1.1x 1.7x 1.9x
Stock comp / revenue 2.0% 2.6% 1.5%

Financial Health

11 metrics
MetricRMDEWABT
Debt / assets 5.0% 4.2% 28.8%
Debt / equity 0.1x 0.1x 0.6x
Net debt / EBITDA -0.3x -2.5x 2.5x
Debt / FCF 0.3x 0.4x 4.6x
Liabilities / assets 27.6% 22.5% 52.3%
Equity / assets 72.4% 77.5% 47.7%
Interest coverage 81.1x – 6.7x
Current ratio 2.6x 4.6x 1.5x
Quick ratio 1.5x 3.5x 0.8x
Cash ratio 0.8x 2.9x 0.3x
Altman Z-score 12.00 14.42 3.36

Shareholder Returns

7 metrics
MetricRMDEWABT
Dividend yield 1.1% – 2.3%
Net buyback yield 4.2% 0.9% 0.7%
Shareholder yield 5.3% 0.9% 3.0%
Payout ratio (earnings) – – 92.0%
Payout ratio (FCF) – – 64.0%
Dividend growth (1Y) – – 6.9%
Dividend CAGR (3Y) – – 7.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRMDEWABT
Forward P/E 18.5xFY2027 37.6xFY2026 19.1xFY2026
EPS, next fiscal year $12.92FY2027 $2.85FY2026 $5.69FY2026
EPS growth, next FY +15.7%FY2027 +11.3%FY2026 +10.5%FY2026
EPS growth, the year after +8.9% +12.6% +10.2%
Revenue, next fiscal year $5.99BFY2027 $7.28BFY2026 $52.99BFY2026
Revenue growth, next FY +6.0%FY2027 +19.9%FY2026 +19.5%FY2026
Revenue growth, the year after -3.8% -2.2% -2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRMDEWABT
Held by institutions 68.7% 90.6% 79.2%
Institutions holding 889 1,326 2,983
Change in shares held, QoQ +3.2% +20.4% +0.3%
Institutions buying 404 641 1,261
Institutions selling 360 456 1,379
Buyers to sellers 1.12 1.41 0.91

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RMDEWABT
RMD 1.00 0.35 0.41
EW 0.35 1.00 0.32
ABT 0.41 0.32 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RMD, EW and ABT?

Abbott Laboratories (ABT) is the largest by market capitalisation: Resmed (RMD) $34.16B, Edwards Lifesciences (EW) $61.58B, Abbott Laboratories (ABT) $186.63B.

Which stock is cheaper, RMD, EW and ABT?

Resmed (RMD) trades on the lowest price-to-earnings ratio (Resmed (RMD) 21.4x, Edwards Lifesciences (EW) 60.7x, Abbott Laboratories (ABT) 39.7x). On next year's consensus earnings, Resmed (RMD) is cheapest (Resmed (RMD) 18.5x, Edwards Lifesciences (EW) 37.6x, Abbott Laboratories (ABT) 19.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Edwards Lifesciences (EW) grew revenue fastest over the trailing twelve months: Resmed (RMD) +9.0%, Edwards Lifesciences (EW) +13.4%, Abbott Laboratories (ABT) +10.0%.

Which company is more profitable?

Resmed (RMD) has the highest net margin (Resmed (RMD) 27.8%, Edwards Lifesciences (EW) 15.2%, Abbott Laboratories (ABT) 9.7%). On return on invested capital, Resmed (RMD) leads (Resmed (RMD) 22.0%, Edwards Lifesciences (EW) 8.7%, Abbott Laboratories (ABT) 5.7%).

Which stock has performed better?

Over the past year Edwards Lifesciences (EW) returned the most: Resmed (RMD) -5.0%, Edwards Lifesciences (EW) +24.5%, Abbott Laboratories (ABT) -16.0%. Over five years, Resmed (RMD) compounded fastest (Resmed (RMD) -1.2%/yr, Edwards Lifesciences (EW) -1.6%/yr, Abbott Laboratories (ABT) -3.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Resmed (RMD) 0.00%, Edwards Lifesciences (EW) 0.00%, Abbott Laboratories (ABT) 0.02%. Resmed (RMD) and Edwards Lifesciences (EW) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Edwards Lifesciences (EW) has been the steadiest (Resmed (RMD) 31.1%, Edwards Lifesciences (EW) 25.5%, Abbott Laboratories (ABT) 28.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RMD, EW and ABT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Resmed (RMD) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.